Why the study?
Do ticlopidine and clopidogrel reduce ischemic events compared with aspirin or placebo in patients with cardiovascular disease?
Population
Patients with cardiovascular disease, including stroke, recent transient ischemic attack, coronary artery…
Comparison
Ticlopidine and clopidogrel vs Placebo, aspirin, or warfarin-based regimens
Design
Review
Authors
Loading...
Supports clopidogrel as aspirin alternative in cardiovascular disease; leaves open optimal antiplatelet selection amid newer agents.
Do ticlopidine and clopidogrel reduce ischemic events compared with aspirin or placebo in patients with cardiovascular disease?
Ticlopidine and clopidogrel provide beneficial antiplatelet effects and reduce ischemic events compared with aspirin in a broad range of patients with cardiovascular disease.
Peter Sharis (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: